FDA clears AngioDynamics' device to reduce blood clots

08/21/2013 | Post-Star (Glens Falls, N.Y.), The · RTT News

The FDA has cleared AngioDynamics to market its BioFlo Port with Endexo system. The device, which is implanted below the skin, is used to minimize the risk of blood clots among patients in need of prolonged or frequent access to the cardiovascular system for chemotherapy and other treatments.

View Full Article in:

Post-Star (Glens Falls, N.Y.), The · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY